Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte-macrophage colony-stimulating factor.

Abstract

The immunological response in healthy subjects to a crude leishmania antigen vaccine (Leishvacin) plus rhGM-CSF without prior Montenegro (DTH) skin testing was evaluated. Fifty-six healthy volunteers received vaccine plus either placebo or rhGM-CSF at day 0, followed by either a vaccine booster or placebo at day 21. IFN-gamma and IL-5 levels were significantly enhanced by day 21. The adjuvant group had a higher percentage of individuals with a significant response to vaccination than the corresponding placebo group. Eighty-six percent of all volunteers were DTH-positive by day 42. Leishvacin is capable of sensitizing lymphocytes from individuals not previously exposed to leishmania antigen. Use of rhGM-CSF enhanced the immune response, indicating that it may improve immunological response to the vaccine.

• Authors: Ivonise Follador, Cibele Araujo, Glória Orge, Lay Har Cheng, Lucas P de Carvalho, Olívia Bacellar, Roque P Almeida, Edgar M Carvalho
• Journal: Vaccine (Vaccine) Vol. 20 Issue 9-10 Pg. 1365-8 (Jan 31 2002) ISSN: 0264-410X [Print] Netherlands
• PMID: 11818154 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Adjuvants, Immunologic
• Interleukin-5
• Protozoan Vaccines
• Recombinant Proteins
• Vaccines, Inactivated
• Interferon-gamma
• Granulocyte-Macrophage Colony-Stimulating Factor

Topics

• Adjuvants, Immunologic (pharmacology)
• Animals
• Double-Blind Method
• Granulocyte-Macrophage Colony-Stimulating Factor (pharmacology)
• Humans
• Hypersensitivity, Delayed (etiology)
• Interferon-gamma (biosynthesis)
• Interleukin-5 (biosynthesis)
• Leishmania mexicana (immunology)
• Protozoan Vaccines (immunology)
• Recombinant Proteins
• Vaccines, Inactivated (immunology)